21 CFR 886.5500
§ 886.5500 Digital therapy device for amblyopia.
United States · 21 CFR — Food and Drugs · Status: effective
Cite this
- Citation
- 21 CFR 886.5500, § 886.5500 Digital therapy device for amblyopia, United States, version 1 as recorded 2026-07-09, yourstate.us, https://yourstate.us/provision/91014
- Permanent ID
ys:prov:91014@1- SHA-256
bb7945cef449bb003a89110d6b03baa8ba8f29a0ba2504cc2e909eff5ccaadd4
The hash is SHA-256 of this version's text, with every run of whitespace collapsed to a single space and the ends trimmed. The ID always leads back here, and checking it says whether the text you cited is still the current version.
Full text
(a) Identification. A digital therapy device for amblyopia is a device that incorporates dichoptic presentations on visual displays through therapeutic algorithms to treat amblyopia or to improve visual acuity of patients with amblyopia.
(b) Classification. Class II (special controls). The special controls for this device are:
(1) Clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use with labeled compatible visual display devices, including evaluation of all adverse events and device performance to improve measures of visual function.
(2) Software verification, validation, and hazard analysis must be performed. Documentation must include characterizations of the technical specifications of the software.
(3) Non-clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use. All visual displays intended for use must undergo compatibility testing to ensure adequate display resolution, luminance, contrast, field of view, image quality, appropriate optical image distance, and verify their compatibility with the software and intended user (such as appropriate interpupillary distance).
(4) Labeling must include the following:
(i) The minimum hardware and operating system requirements that support the software of the device;
(ii) The models of the visual displays validated to be compatible with this device;
(iii) The length of treatment and/or retreatment supported by clinical performance testing; and
(iv) A summary of the clinical performance testing conducted with the device.
(5) Labeling comprehension testing with intended users must be performed.
Legislative history
This is a federal regulation, adopted through agency rulemaking under the Administrative Procedure Act — not enacted by a recorded vote of Congress.